Cerebrospinal Fluid Biomarkers in the Longitudinal Early-onset Alzheimer's Disease Study

Introduction: One goal of the Longitudinal Early Onset Alzheimer's Disease Study (LEADS) is to define the fluid biomarker characteristics of early-onset Alzheimer's disease (EOAD).

Methods: Cerebrospinal fluid (CSF) concentrations of Aβ1-40, Aβ1-42, total tau (tTau), pTau181, VILIP-1, SNAP-25, neurogranin (Ng), neurofilament light chain (NfL), and YKL-40 were measured by immunoassay in 165 LEADS participants. The associations of biomarker concentrations with diagnostic group and standard cognitive tests were evaluated.

Results: Biomarkers were correlated with one another. Levels of CSF Aβ42/40, pTau181, tTau, SNAP-25, and Ng in EOAD differed significantly from cognitively normal and early-onset non-AD dementia; NfL, YKL-40, and VILIP-1 did not. Across groups, all biomarkers except SNAP-25 were correlated with cognition. Within the EOAD group, Aβ42/40, NfL, Ng, and SNAP-25 were correlated with at least one cognitive measure.

Discussion: This study provides a comprehensive analysis of CSF biomarkers in sporadic EOAD that can inform EOAD clinical trial design.

Citing Articles

Differences in baseline cognitive performance between participants with early-onset and late-onset Alzheimer's disease: Comparison of LEADS and ADNI.

Hammers D, Eloyan A, Thangarajah M, Taurone A, Beckett L, Gao S Alzheimers Dement. 2024; 21(1):e14218.

PMID: 39711228 PMC: 11772709. DOI: 10.1002/alz.14218.

Unveiling the multifaceted pathogenesis and therapeutic drugs of Alzheimer's disease: A comprehensive review.

Peng L, Zhang Z, Li Q, Song Z, Yan C, Ling H Heliyon. 2024; 10(20):e39217.

PMID: 39629139 PMC: 11612466. DOI: 10.1016/j.heliyon.2024.e39217.

Dynamics of synaptic damage in severe traumatic brain injury revealed by cerebrospinal fluid SNAP-25 and VILIP-1.

Heuvel F, Li Z, Riedel D, Halbgebauer S, Oeckl P, Mayer B J Neurol Neurosurg Psychiatry. 2024; 95(12):1158-1167.

PMID: 38825349 PMC: 11671962. DOI: 10.1136/jnnp-2024-333413.

Recently Updated Role of Chitinase 3-like 1 on Various Cell Types as a Major Influencer of Chronic Inflammation.

Mizoguchi E, Sadanaga T, Nanni L, Wang S, Mizoguchi A Cells. 2024; 13(8.

PMID: 38667293 PMC: 11049018. DOI: 10.3390/cells13080678.

References

Besser L, Kukull W, Knopman D, Chui H, Galasko D, Weintraub S . Version 3 of the National Alzheimer's Coordinating Center's Uniform Data Set. Alzheimer Dis Assoc Disord. 2018; 32(4):351-358. PMC: 6249084. DOI: 10.1097/WAD.0000000000000279. View

Harvey R, Skelton-Robinson M, Rossor M . The prevalence and causes of dementia in people under the age of 65 years. J Neurol Neurosurg Psychiatry. 2003; 74(9):1206-9. PMC: 1738690. DOI: 10.1136/jnnp.74.9.1206. View

Pontecorvo M, Lu M, Burnham S, Schade A, Dage J, Shcherbinin S . Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial. JAMA Neurol. 2022; 79(12):1250-1259. PMC: 9577883. DOI: 10.1001/jamaneurol.2022.3392. View

Fagan A, Xiong C, Jasielec M, Bateman R, Goate A, Benzinger T . Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. Sci Transl Med. 2014; 6(226):226ra30. PMC: 4038930. DOI: 10.1126/scitranslmed.3007901. View

Sutphen C, Jasielec M, Shah A, Macy E, Xiong C, Vlassenko A . Longitudinal Cerebrospinal Fluid Biomarker Changes in Preclinical Alzheimer Disease During Middle Age. JAMA Neurol. 2015; 72(9):1029-42. PMC: 4570860. DOI: 10.1001/jamaneurol.2015.1285. View

Mattsson N, Insel P, Palmqvist S, Portelius E, Zetterberg H, Weiner M . Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease. EMBO Mol Med. 2016; 8(10):1184-1196. PMC: 5048367. DOI: 10.15252/emmm.201606540. View

ROSEN W, Mohs R, Davis K . A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984; 141(11):1356-64. DOI: 10.1176/ajp.141.11.1356. View

. 2022 Alzheimer's disease facts and figures. Alzheimers Dement. 2022; 18(4):700-789. DOI: 10.1002/alz.12638. View

Marra C, Bizzarro A, Daniele A, De Luca L, Ferraccioli M, Valenza A . Apolipoprotein E epsilon4 allele differently affects the patterns of neuropsychological presentation in early- and late-onset Alzheimer's disease patients. Dement Geriatr Cogn Disord. 2004; 18(2):125-31. DOI: 10.1159/000079191. View

10.

Sutphen C, McCue L, Herries E, Xiong C, Ladenson J, Holtzman D . Longitudinal decreases in multiple cerebrospinal fluid biomarkers of neuronal injury in symptomatic late onset Alzheimer's disease. Alzheimers Dement. 2018; 14(7):869-879. PMC: 6110083. DOI: 10.1016/j.jalz.2018.01.012. View

11.

Cho H, Choi J, Lee S, Lee J, Choi Y, Ryu Y . Excessive tau accumulation in the parieto-occipital cortex characterizes early-onset Alzheimer's disease. Neurobiol Aging. 2017; 53:103-111. DOI: 10.1016/j.neurobiolaging.2017.01.024. View

12.

Willemse E, Tijms B, van Berckel B, Le Bastard N, van der Flier W, Scheltens P . Comparing CSF amyloid-beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status. Alzheimers Dement (Amst). 2021; 13(1):e12182. PMC: 8088096. DOI: 10.1002/dad2.12182. View

13.

Galasko D, Xiao M, Xu D, Smirnov D, Salmon D, Dewit N . Synaptic biomarkers in CSF aid in diagnosis, correlate with cognition and predict progression in MCI and Alzheimer's disease. Alzheimers Dement (N Y). 2019; 5:871-882. PMC: 6911971. DOI: 10.1016/j.trci.2019.11.002. View

14.

Apostolova L, Aisen P, Eloyan A, Fagan A, Fargo K, Foroud T . The Longitudinal Early-onset Alzheimer's Disease Study (LEADS): Framework and methodology. Alzheimers Dement. 2021; 17(12):2043-2055. PMC: 8939858. DOI: 10.1002/alz.12350. View

15.

Olsson B, Lautner R, Andreasson U, Ohrfelt A, Portelius E, Bjerke M . CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 2016; 15(7):673-684. DOI: 10.1016/S1474-4422(16)00070-3. View

16.

Molinuevo J, Ayton S, Batrla R, Bednar M, Bittner T, Cummings J . Current state of Alzheimer's fluid biomarkers. Acta Neuropathol. 2018; 136(6):821-853. PMC: 6280827. DOI: 10.1007/s00401-018-1932-x. View

17.

Willemse E, van Maurik I, Tijms B, Bouwman F, Franke A, Hubeek I . Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project. Alzheimers Dement (Amst). 2018; 10:563-572. PMC: 6215060. DOI: 10.1016/j.dadm.2018.08.006. View

18.

Neth B, Graff-Radford J, Mielke M, Przybelski S, Lesnick T, Schwarz C . Relationship Between Risk Factors and Brain Reserve in Late Middle Age: Implications for Cognitive Aging. Front Aging Neurosci. 2020; 11:355. PMC: 6962238. DOI: 10.3389/fnagi.2019.00355. View

19.

Aschenbrenner A, Li Y, Henson R, Volluz K, Hassenstab J, Verghese P . Comparison of plasma and CSF biomarkers in predicting cognitive decline. Ann Clin Transl Neurol. 2022; 9(11):1739-1751. PMC: 9639639. DOI: 10.1002/acn3.51670. View

20.

Toyota Y, Ikeda M, Shinagawa S, Matsumoto T, Matsumoto N, Hokoishi K . Comparison of behavioral and psychological symptoms in early-onset and late-onset Alzheimer's disease. Int J Geriatr Psychiatry. 2007; 22(9):896-901. DOI: 10.1002/gps.1760. View